BioAge Labs (BIOA) Revenue (2025 - 2026)
BioAge Labs (BIOA) reported Revenue of $2.8 million for Q1 2026, up 91.04% on a YoY basis from $1.5 million in Q1 2025, and down 9.94% sequentially from $3.1 million in Q4 2025.
BioAge Labs (BIOA) Revenue (2025 - 2026) Analysis & Trends
BioAge Labs (BIOA) has 2 years of Revenue data on file, last reported at $2.8 million in Q1 2026.
- For the quarter ending Q1 2026, Revenue rose 91.04% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $10.3 million (up 610.96% YoY), and the FY2025 full-year result was $9.0 million, changed N/A from the prior year.
- Revenue declined to $2.8 million in Q1 2026, from $3.1 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $3.1 million in Q4 2025 to a low of $1.5 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.98 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.26 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 6.98 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 781.50 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 3.51 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 814.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.37 Bn |
| 10 | BioAge Labs | 930.32 Mn | 930.32 Mn | -10.37 Mn | 2.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.77 Mn |
| Dec 31, 2025 | 3.08 Mn |
| Sep 30, 2025 | 2.05 Mn |
| Jun 30, 2025 | 2.41 Mn |
| Mar 31, 2025 | 1.45 Mn |